Overview

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to to explore the efficacy and safety of PD-1 immune check point inhibitor, sintilimab, in biomarker-selected subjects with advanced or metastatic Non-small Cell Lung Cancer who have failed from standard front-line treatment.

Phase:

Phase 2

Details

Lead Sponsor:

China Medical University, China

Collaborators:

Anshan Tumor Hospital
Benxi Cental Hospital
Liaoning Cancer Hospital & Institute
Shengjing Hospital
The First Affiliated Hospital of Dalian Medical University
The First People's Hospital of Jingzhou
The People's Hospital of Liaoning Province
The Second Affiliated Hospital of Dalian Medical University